Cumberland Pharmaceuticals Inc (CPIX) - Total Liabilities
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has total liabilities worth $49.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Cumberland Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Cumberland Pharmaceuticals Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Cumberland Pharmaceuticals Inc to measure how efficiently the company converts operating cash flow to free cash.
Cumberland Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Helio SA
WAR:HEL
|
Poland | zł169.14 Million |
|
Sunshine Metals Ltd
AU:SHN
|
Australia | AU$2.43 Million |
|
KEYEAST.Co.Ltd
KQ:054780
|
Korea | ₩19.16 Billion |
|
BitNine Co. Ltd.
KQ:357880
|
Korea | ₩22.04 Billion |
|
Amata VN PCL
BK:AMATAV
|
Thailand | ฿7.34 Billion |
|
Regis Corporation Common Stock
NASDAQ:RGS
|
USA | $367.15 Million |
|
Clime Capital Ltd
AU:CAM
|
Australia | AU$43.06 Million |
|
Alliance Aviation Services Ltd
AU:AQZ
|
Australia | AU$718.22 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Cumberland Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cumberland Pharmaceuticals Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cumberland Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual total liabilities of Cumberland Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $52.28 Million | -1.43% |
| 2024-12-31 | $53.04 Million | +0.99% |
| 2023-12-31 | $52.52 Million | -7.79% |
| 2022-12-31 | $56.95 Million | +36.06% |
| 2021-12-31 | $41.86 Million | -15.59% |
| 2020-12-31 | $49.59 Million | -7.25% |
| 2019-12-31 | $53.46 Million | -6.41% |
| 2018-12-31 | $57.12 Million | +94.89% |
| 2017-12-31 | $29.31 Million | +44.50% |
| 2016-12-31 | $20.28 Million | +34.34% |
| 2015-12-31 | $15.10 Million | +3.05% |
| 2014-12-31 | $14.65 Million | +76.07% |
| 2013-12-31 | $8.32 Million | -36.12% |
| 2012-12-31 | $13.03 Million | +2.71% |
| 2011-12-31 | $12.68 Million | -11.55% |
| 2010-12-31 | $14.34 Million | -54.49% |
| 2009-12-31 | $31.50 Million | +132.25% |
| 2008-12-31 | $13.56 Million | +11.43% |
| 2007-12-31 | $12.17 Million | -20.73% |
| 2006-12-31 | $15.36 Million | +289.76% |
| 2005-12-31 | $3.94 Million | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more